CClinicalTrials.gg
Status unknownNCT03288558Updated Apr 30, 2021

Protective Mechanical VENTilation Strategy in Patients Undergoing CARDiac Surgery

An interventional study of A comprehensive perioperative mechanical ventilation strategy in Pulmonary Complications and Cardiac Surgery, sponsored by University Health Network, Toronto. Status unknown at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-04-30.

Sponsored by University Health Network, Toronto · Not applicable, Interventional, and Prevention

The sponsor has not verified this record recently (last verified Apr 2021), so the status shown — last known as Recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
310
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Heart surgery is a life-saving intervention for hundreds of thousands of patients each year worldwide. Advances in technology and medical expertise have improved outcomes for these patients over the years. However, despite such advances, approximately 30% of patients develop lung complications (also called "pulmonary complications") after heart surgery, which result in prolonged hospital stay, increased mortality and healthcare costs.

During and immediately after heart surgery, the patient's breathing needs to be artificially controlled by a breathing machine, called "mechanical ventilator". The medical literature has reported that in critically ill patients the use of specific settings on the breathing machine (so called "protective mechanical ventilation") prevents lung complications and significantly decreases mortality. Studies show that such settings could also be beneficial for patients that undergo several types of planned surgery, however data regarding heart surgery patients (the most vulnerable to lung complications) are lacking.The aim of our study is to test whether the use of protective mechanical ventilation settings during and after heart surgery reduces lung complications compared to the current standard of care. The main innovation of this study is the application of a novel protective mechanical ventilation strategy to patients undergoing cardiac surgery, in order to reduce post-operative pulmonary complications.

Read the detailed description

Postoperative pulmonary complications are frequent after cardiac surgery, affecting approximately 30% of all patients. Such complications result in increased morbidity, mortality and health care utilization. During and immediately after surgery, mechanical ventilation is required to control the patient's breathing. Recent scientific literature showed the striking importance of specific mechanical ventilation settings (which often constituted a bundle of interventions and were generally called "protective mechanical ventilation") in other areas of medicine (i.e., critical care, abdominal surgery, management of organ donors) to prevent the onset or propagation of lung injury as well as multiple organ dysfunction. These protective settings include tidal volume of 6 ml/kg of ideal body weight (as opposed to the traditional tidal volume of 10-12 ml/kg), use of positive end expiratory pressure (PEEP), recruitment maneuvers (temporary periodic application of higher respiratory pressures or volumes on the mechanical ventilator in order to re-open collapsed areas of the lungs) and attention at avoiding lung collapse during patient transfer and suctioning (i.e. maintaining PEEP during transfer and avoiding disconnection from the breathing circuit during suctioning of respiratory secretions). Such interventions could play an even more important role during cardiac surgery, where several insults to the lung take place. These insults result from the inflammatory cascade triggered by cardiopulmonary bypass (CPB), myocardial injury and areas of lung collapse (atelectasis). Indeed, a recent retrospective study showed that the tidal volume utilized during and after cardiac surgery impacts significantly on organ dysfunction, with a tidal volume less than 10 ml/kg of ideal body weight providing better outcomes than larger tidal volumes.

The investigators hypothesize that our proposed bundle of protective mechanical ventilation settings aimed at minimizing lung injury by continuation of mechanical ventilation during cardiopulmonary bypass, recruitment maneuvers, and use of systems that prevent lung collapse during patient transfer and suctioning (i.e. PEEP valves and closed respiratory circuits) will reduce postoperative pulmonary complications compared to the current standard of care, hence significantly improving patients outcomes and reducing health care costs.

02

Conditions studied

  • Pulmonary Complications
  • Cardiac Surgery
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Age > 18 years old
  • Scheduled for elective Coronary Artery Bypass Graft, Single valve repair or replacement, or Coronary Artery Bypass Graft plus Single Valve repair or replacement, with the use of Cardiopulmonary Bypass (CPB), aortic clamp and cardioplegia, sternotomy

Exclusion criteria

Exclusion Criteria:

  • Pregnancy
  • Clinically significant Congenital Heart Disease
  • Surgery with planned thoracotomy approach with one lung ventilation
  • Body mass index (the weight in kilograms divided by the square of the height in meters) of 40 or higher,
  • Receipt of positive pressure mechanical ventilation (invasive and non-invasive) within the 2 weeks preceding surgery (excluding routine treatment for obstructive sleep apnea syndrome)
  • Severe chronic respiratory disease, as indicated by any of:
  • Baseline FEV1 \< 20 ml/kg predicted body weight
  • Pre-existing chronic interstitial lung disease with chronic interstitial infiltration on chest X-ray
  • Documented chronic CO2 retention (PaCO2 > 50 mm Hg) and/or chronic hypoxaemia (PaO2\<55 mmHg on FiO2 = 0.21)
  • Chronic restrictive, obstructive, neuromuscular, chest wall or pulmonary vascular disease resulting in severe exercise restriction (e.g., unable to climb stairs or perform household duties), secondary polycythaemia, severe pulmonary hypertension (mean PAP > 40 mmHg), or ventilator dependency
  • Requirement for urgent/emergent surgery
  • Progressive neuromuscular illness* that will result in prolonged need for mechanical ventilation
  • Previous randomization in this trial
  • Consent refusal
  • Surgeon, anesthesiologist, intensivist refusal
04

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
310 participants (estimated)

Study arms

  • Experimental
    Intervention Group

    Subjects randomized to the intervention group will receive a comprehensive perioperative mechanical ventilation strategy that includes a bundle of protective settings (use of PEEP, recruitment maneuvers and continuation of mechanical ventilation during CPB).

    Other: A comprehensive perioperative mechanical ventilation strategy

  • No intervention
    Control Group

    Subjects randomized to the control group will receive mechanical ventilation according to the current usual care.

Interventions

  • OtherA comprehensive perioperative mechanical ventilation strategy

    1) Intervention group. * Recruitment maneuvers (doubling the tidal volumes for 10 consecutive breaths) every 30min and after every time mechanical ventilation is stopped for surgical reasons, suctioning occurs or the breathing circuit is disconnected * Mechanical ventilation will be continued during CPB (PEEP 5 cm H2O, respiratory rate 8/min, Tidal Volume 6 ml/kg PBW, FiO2 21% * Avoidance of lung de-recruitment during patient's transfer (use of PEEP via PEEP valves, endotracheal tube clamps during disconnection from the breathing circuit) * Avoidance of disconnection from respiratory circuit during respiratory secretions suctioning (applying closed suction circuits) * For the remaining aspects the mechanical ventilation settings will be the same as in the control group. Tidal volume 6ml/kg PBW PEEP 5cm H20 FiO2 to target SatO2 of 92-97% Discontinuation of mechanical ventilation during cardiopulmonary bypass

05

What researchers measure

Primary outcomes

  1. Post-operative pulmonary complications

    Daily chart review and assessment of any pulmonary complications documented

    Time frame: for 7 days post operatively

Secondary outcomes

  1. Ventilator free days

    number of days without a ventilator Number of days without ventilation

    Time frame: Post op day 1-28 days

  2. Intensive care length of stay

    Number of days in the intensive care unit

    Time frame: Post op day 1-28 days

  3. Hospital length of stay

    Number of days in the hospital

    Time frame: Post op day 1-28 days

  4. Duration of mechanical ventilation

    Length of time on a ventilator

    Time frame: Post op day 1-28 days

  5. Ease of surgical access

    Ability of the surgeon to access the surgical field during cardiopulmonary bypass using a 5 point Likert scale

    Time frame: Intraoperatively during surgery

  6. Barotrauma

    defined as radiological evidence of pneumothorax and/or pneumomediastinum

    Time frame: in the first 7 days after surgery

  7. Surgical complications

    death, myocardial infarction, stroke, acute liver injury, and chest reopening

    Time frame: From the day of surgery to 48 hours post surgery

  8. Acute Kidney Injury

    Incidence of Acute Kidney Injury across the study population

    Time frame: Day of surgery to 28 days

  9. Mortality

    Incidence of mortality across the study population

    Time frame: Day of surgery to 90-day

  10. Home and alive

    to evaluate days at home

    Time frame: up to 30 days after surgery

06

Study locations

1 of 1 sites recruiting
  • Toronto General Hospital, University Health Network
    Toronto, Ontario M5G 2C4, Canada
    Recruiting
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT03288558
Lead sponsor
University Health Network, Toronto
Responsible party
Jo Carroll (Manager Anesthesia Research, University Health Network, Toronto) — Principal investigator
First posted
Sep 20, 2017
Start date
Jul 7, 2017
Primary completion
Dec 30, 2021 (estimated)
Completion
Apr 1, 2022 (estimated)
Last update
Apr 30, 2021

Study contacts

Matteo Parotto, MD, PhD
Contact
matteo.parotto@uhn.ca
416-340-4800 ext. 5877
Matteo Parotto, MD, PhD
principal investigator · Toronto General Hospital, UHN

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion